Aussie MGC Pharmaceuticals rises after EU certification to Malta plant

Argent BioPharma

02/05/2023 06:46

** Shares of MGC Pharmaceuticals  MXC.AX  rise as much as
12.5% to A$0.009, hitting their highest since April 19
    ** Stock eyes best day since April 21
    ** The biopharma company says co's Malta production facility
granted formal EU-Good Manufacturing Practice (GMP)
certification 
    ** Adds, as a fully GMP certified facility, MGC will be able
to provide third party production services to other pharma
companies and maximise its manufacturing capacity potential to
deliver additional revenue stream 
    ** MXC has fallen over 27% this year, as of last close

 (Reporting by Nausheen Thusoo in Bengaluru)
 ((Nausheen.Thusoo@thomsonreuters.com;))